Anna Kalff

4PUBLICATIONS
20CO-AUTHORS
Gene and molecular therapyHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Sep 22, 2026
Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 ALLG MM23 (SeaLAND) trial.

|Jun 26, 2023
A sequential cohort study evaluating single-agent KappaMab and KappaMab combined with lenalidomide and low-dose dexamethasone in relapsed and/or refractory kappa light chain-restricted multiple myeloma (AMaRC 01-16).

Andrew Spencer, Anna Kalff, Jake Shortt

|Jun 18, 2023
Response adaptive salvage with KTd and ASCT for functional high-risk multiple myeloma-The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial.

R Turner, H Quach, N Horvath

|May 15, 2021
A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16-02 trial.

Krystal Bergin, Flora Yuen, Craig Wallington-Beddoe

Pageof 1

Frequent Collaborators

3 joint publications

Hang Quach

2 joint publications

Andrew Spencer

1 joint publications

Krystal Bergin

1 joint publications

Craig Wallington-Beddoe